Dr Richard Butt
Apollo Therapeutics CEO
Dr Richard Butt has 20 years’ experience in pharmaceutical drug discovery and development from working on the earliest novel ideas to Ph3 programmes. Richard is a cell biologist with a degree in biochemistry from the University of York and PhD from University College London, from where he joined Pfizer in 1996. Richard developed his technical experience and leadership skills as a lead biologist across multiple therapy areas, within drug safety/safety pharmacology and for the last few years leading clinical translational strategy in the Pain and Neuroscience therapy area. Richard has lead 7 programmes to clinical candidate selection, developed IND/CTA-enabling and preclinical regulatory packages for many assets, and led >30 clinical studies spanning Ph0 to Ph2 designs, execution and delivery. Richard’s passion is in project and portfolio leadership in the pre-clinical and clinical translational space and this fits perfectly with the remit and mission of Apollo Therapeutics and as leader of the drug discovery team.